PRAK-03202: A triple antigen virus-like particle vaccine candidate against SARS CoV-2
Saumyabrata Mazumder, Ruchir Rastogi, Avinash Undale, Kajal Arora, Nupur Mehrotra Arora, Biswa Pratim, Dilip Kumar, Abyson Joseph, Bhupesh Mali, Vidya Bhushan Arya, Sriganesh Kalyanaraman, A.K. Mukherjee, Aditi Gupta, Swaroop Potdar, Sourav Singha Roy, Deepak Parashar, Jeny Paliwal, Sudhir Kumar Singh, Aelia Naqvi, Apoorva Srivastava, Manglesh Kumar Singh, Devanand Kumar, Sarthi Bansal, Satabdi Rautray, Manish Ranjan Saini, Kshipra Jain, Reeshu Gupta, Prabuddha K. Kundu
Abstract
-based D-Crypt™ platform, which induced SARS CoV-2 specific neutralizing antibodies in BALB/c mice. Immunization using three different doses of PRAK-03202 induced an antigen-specific (spike, envelope, and membrane proteins) humoral response and neutralizing potential. Peripheral blood mononuclear cells from convalescent patients showed lymphocyte proliferation and elevated interferon levels suggestive of epitope conservation and induction of T helper 1-biased cellular immune response when exposed to PRAK-03202. These data support further clinical development and testing of PRAK-03202 for use in humans.